The
Naval Blood Research Laboratory (NBRL), under the direction of
C. Robert Valeri, M.D. (Capt, MC, USNRet) was once a U.S. Navy
laboratory, a government-owned, contractor-operated facility and
is now known as NBRL, Inc. The mission of the laboratory is now
and always has been to develop blood products and methods to treat
military and civilian casualties. Funding for the laboratory in
the past has been provided primarily by grants from the Navy's
Bureau of Medicine and Surgery and Office of Naval Research (ONR)
as well as the U.S. Congress.
Major
accomplishments over the years include developing the procedure
to freeze red blood cells with glycerol, obtaining FDA approval
for this red blood cell freezing procedure, obtaining FDA approval
for rejuvenating both indated and outdated red blood cells using
the NBRL-developed PIPA solution, obtaining FDA approval to prolong
the storage of fresh frozen plasma from 1 year to 7 years, obtaining
FDA approval for an automated, closed system (the Haemonetics ACP215)
to glycerolize and deglycerolize red blood cells to allow for an
extension of the post-wash storage period from 1 day to 2 weeks,
and the submission of data to obtain FDA approval for DMSO-frozen
platelets.
The NBRL is currently planning research in collaboration with the
U.S. Army to evaluate a new method to freeze platelets with DMSO
and a new resuscitative solution containing ketones which may potentially
be used to treat wounded servicemen.
Funding
from the laboratory comes from NBRL’s response to
requests for proposals from government and non-government sources.